UNSPSC 51282123: Sulopenem

This classification denotes a beta-lactam antibiotic with the molecular formula C12H15NO5S3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier XX514BJ1XW, chemically known as 4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-((tetrahydro-3-thienyl)thio)-, s-oxide, (5r-(3(1r*,3s*),5alpha,6alpha(r*)))- but more generally known as sulopenem, which bears U.S. National Institutes of Health Compound Identifier 71341.

UNSPSC 51282123 Sulopenem (Commodity) does not appear in the recent state and local contract opportunities provided; the code shows no relevant recent solicitation activity. The opportunities tagged under this code span naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmaceutical prescriptions (Texas HHS Commission), emergency medical and first aid supplies (City of Tampa), and generic multi-source pharmaceuticals through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance and Oregon)—none of which directly concern sulopenem procurement. The mismatch between the code's nominal scope and the work actually being bought suggests either tagging inconsistency in state and local procurement systems or that sulopenem demand falls outside current state and local purchasing patterns. A business development professional evaluating this code should verify whether the code is actively used by the target jurisdictions or whether sulopenem procurement, when it occurs, is tagged differently in practice.

If sulopenem demand emerges in state and local purchasing, it would likely flow through cooperative pharmaceutical agreements (as evidenced by MMCAP's generic pharmaceutical contracts) or institutional health-system procurements, rather than as a standalone commodity. Monitor Minnesota Department of Administration, state health departments, and hospital purchasing consortia for future pharmaceutical RFPs that may include beta-lactam antibiotics or specialty antimicrobial agents; cooperative vehicles such as MMCAP represent the most common contracting pathway for pharmaceutical products in the state and local space.